Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Breast Cancer : Basic and Clinical Research
|
September 30, 2015
Everolimus in the Treatment of Metastatic Breast Cancer
Melanie E Royce, Diaa Osman
Breast Cancer Research and Treatment
|
October 12, 2011
The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer
Dulcinea Candelaria-Quintana, Zoneddy R Dayao, Melanie E Royce
Surgery
|
January 5, 2010
Bone scan demonstration of osteoblastic tumor of the breast
Anne Marie Wallace, Robert D Rosenberg, Melanie E Royce
The Medical Clinics of North America
|
August 30, 2008
Breast disease: benign and malignant
Angela L W Meisner, M Houman Fekrazad, Melanie E Royce
Bioorganic & Medicinal Chemistry Letters
|
September 11, 2013
Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides
Haixun Guo, Helen Hathaway, Melanie E Royce, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 15, 2014
Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides
Jie Lu, Helen J Hathaway, Melanie E Royce, et al.
Bioconjugate Chemistry
|
July 14, 2011
Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides
Haixun Guo, Jie Lu, Helen Hathaway, et al.
American Journal of Clinical Oncology
|
October 9, 2007
Idiopathic granulomatous lobular mastitis masquerading as a breast abscess and breast carcinoma
Dalice A Marriott, John Russell, James Grebosky, et al.
Frontiers in Genetics
|
December 21, 2016
The rs4646 and rs12592697 Polymorphisms in <i>CYP19A1</i> Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds
Reina Armamento-Villareal, Vallabh O Shah, Lina E Aguirre, et al.
Investigational New Drugs
|
January 7, 2004
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum
Melanie E Royce, Eric K Rowinsky, Paulo M Hoff, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Breast Cancer : Basic and Clinical Research
|
September 30, 2015
Everolimus in the Treatment of Metastatic Breast Cancer
Melanie E Royce, Diaa Osman
Breast Cancer Research and Treatment
|
October 12, 2011
The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer
Dulcinea Candelaria-Quintana, Zoneddy R Dayao, Melanie E Royce
Surgery
|
January 5, 2010
Bone scan demonstration of osteoblastic tumor of the breast
Anne Marie Wallace, Robert D Rosenberg, Melanie E Royce
The Medical Clinics of North America
|
August 30, 2008
Breast disease: benign and malignant
Angela L W Meisner, M Houman Fekrazad, Melanie E Royce
Bioorganic & Medicinal Chemistry Letters
|
September 11, 2013
Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides
Haixun Guo, Helen Hathaway, Melanie E Royce, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 15, 2014
Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides
Jie Lu, Helen J Hathaway, Melanie E Royce, et al.
Bioconjugate Chemistry
|
July 14, 2011
Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides
Haixun Guo, Jie Lu, Helen Hathaway, et al.
American Journal of Clinical Oncology
|
October 9, 2007
Idiopathic granulomatous lobular mastitis masquerading as a breast abscess and breast carcinoma
Dalice A Marriott, John Russell, James Grebosky, et al.
Frontiers in Genetics
|
December 21, 2016
The rs4646 and rs12592697 Polymorphisms in <i>CYP19A1</i> Are Associated with Disease Progression among Patients with Breast Cancer from Different Racial/Ethnic Backgrounds
Reina Armamento-Villareal, Vallabh O Shah, Lina E Aguirre, et al.
Investigational New Drugs
|
January 7, 2004
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum
Melanie E Royce, Eric K Rowinsky, Paulo M Hoff, et al.
Page
of 2